The G-BA Innovation Committee recommends transfer to standard care for another three projects in Germany

08

Mar 2023

On February 23, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to preventing the family risk of colorectal carcinoma, shared decision-making in the hospitals, and digitally supported drug therapy management.

The “FARKOR – Prevention in family risk of colorectal carcinoma” project tested various access routes to identify people with a family history of increased risk of colorectal cancer to be able to offer them an immunochemical fecal occult blood test (iFOBT) or a colonoscopy as an early detection test. In addition, detection rates and the distribution of stages of colorectal cancer were collected from the people examined and linked to routine data. It was also possible to make a statement on the frequency of participation and influencing factors. With the help of the FARKOR project, a strategy for the early detection of colorectal cancer was developed and evaluated, aimed at people aged 25 to 50 with a family history of increased risk.

The “MAKING SDM A REALITY – full implementation of shared decision making in the hospital” project combined various measures to successfully anchor shared decision-making (SDM) in everyday clinical practice: training modules for physicians and other health professionals, a campaign to activate patients and 80 newly developed, scientifically based online decision-making tools.

In the “AdAM - Application of digitally supported drug therapy and care management” project, the introduction of digitally supported drug therapy management was tested at the participating general practitioners' practices: practices can be supported in recognizing medication and dosage risks better and faster.

The detailed results of the projects are now being forwarded to the relevant organizations and institutions in the healthcare sector. In this regard, the respective stakeholders are requested to review the results and consider them within their area of responsibility as much as possible, specifically concerning the quality assurance aspect.

The full details in German can be found here, here (the decision and the results of the FARKOR project), here (the decision and the results of the MAKING SDM A REALITY project), and here (the decision and the results of the AdAM project).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

23

Mar 2023

In February 2023, the Scottish Health Technology Group, SHTG, released three MedTech-related assessments: selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma, Feeling Good app, store-and-forward teledermatology for triage of primary care referrals.

Read more

22

Mar 2023

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

Read more

21

Mar 2023

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system for lung volume reduction under Forfait innovation program.

Read more

20

Mar 2023

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics. Twelve new codes concerning clinical biology, molecular biology for infections, and genetics were implemented.

Read more

17

Mar 2023

On March 2, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for new forms of care. A total of six prioritized topics are defined. The preparation of a complete application can be supported for a period of up to six months with a grant of up to a maximum of €75,000. The deadline for submitting ideas is May 16, 2023.

Read more